The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses

Molecular Pharmacology

Volumn 81, Issue 2, 2012, Pages 113-119

  Yuen, Eunice Y ^a   Li, Xiangning ^a   Wei, Jing ^a   Horiguchi, Masakuni ^b,c   Meltzer, Herbert Y ^b   Yan, Zhen ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LURASIDONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; SCHIZOPHRENIA; SPRAGUE DAWLEY RAT; SYNAPTIC TRANSMISSION;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; ISOINDOLES; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; THIAZOLES;

EID: 84862907507     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.076141     Document Type: Article

References (40)

1. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, and Roth BL (2009) Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 205:119-128.
2. 2+/calmodulin-sensitive adenylyl cyclases by the Gs-coupled 5-hydroxytryptamine subtype 5-HT7A receptor. J Biol Chem 273:17469-17476.
3. Béïque JC, Campbell B, Perring P, Hamblin MW, Walker P, Mladenovic L, and Andrade R (2004) Serotonergic regulation of membrane potential in developing rat prefrontal cortex: coordinated expression of 5-hydroxytryptamine (5-HT)1A, 5-HT2A, and 5-HT7 receptors. J Neurosci 24:4807-4817. (Pubitemid 38668205)
4. Citrome L (2011) Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses 4:251-257.
5. Creese I, Burt DR, and Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481-483.
6. Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, and Ito A (2008) Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 186:197-207. (Pubitemid 350122756)
7. Fumagalli F, Calabrese F, Luoni A, Bolis F, Racagni G, and Riva MA (2011) Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int J Neuropsychopharmacol 24:1-12.
8. Fumagalli F, Frasca A, Racagni G, and Riva MA (2008) Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Mol Pharmacol 73:1484-1490. (Pubitemid 351574838)
9. Gasbarri A, Cifariello A, Pompili A, and Meneses A (2008) Effect of 5-HT(7) antagonist SB-269970 in the modulation of working and reference memory in the rat. Behav Brain Res 195:164-170.
10. Hedlund PB, Huitron-Resendiz S, Henriksen SJ, and Sutcliffe JG (2005) 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. Biol Psychiatry 58:831-837. (Pubitemid 41677422)
11. Horiguchi M, Huang M, and Meltzer HY (2011) The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 338:605-614.
12. Iasevoli F, Tomasetti C, Marmo F, Bravi D, Arnt J, and de Bartolomeis A (2010) Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology (Berl) 212:329-344.
13. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, et al. (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334:171-181.
14. Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, and Ohno Y (2007) Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 572:160-170. (Pubitemid 47429645)
15. Javitt DC and Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
16. Jentsch JD and Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225. (Pubitemid 29067401)
17. Jentsch JD, Tran A, Le D, Youngren KD, and Roth RH (1997) Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17: 92-99.
18. Lewis DA and Lieberman JA (2000) Catching up on schizophrenia: natural history and neurobiology. Neuron 28:325-334.
19. Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, et al. (2007) WAY-163909 ((7bR,10aR)- 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole): a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320:486-496. (Pubitemid 46025760)
20. Meltzer HY (1992) Dimensions of outcome with clozapine. Br J Psychiatry Suppl (17):46-53.
21. Meltzer HY (1994) An overview of the mechanism of action of clozapine. J Clin Psychiatry 55 (Suppl B):47-52.
22. Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH Schweizer E, Pikalov A, and Loebel A (2011a) Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 168:957-967.
23. Meltzer HY, Horiguchi M, and Massey BW (2011b) The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 213:289-305.
24. Meltzer HY and Huang M (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172:177-197.
25. Meltzer HY, Matsubara S, and Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246.
26. Meyer JM, Loebel AD, and Schweizer E (2009) Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 18:1715-1726.
27. Mnie-Filali O, Lambas-Señas L Scarna H, and Haddjeri N (2009) Therapeutic potential of 5-HT7 receptors in mood disorders. Curr Drug Targets 10:1109-1117.
28. Mohn AR, Gainetdinov RR, Caron MG, and Koller BH (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98: 427-436. (Pubitemid 29402481)
29. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, and Loebel A (2009) Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 70:829-836.
30. Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, and Schwartz JC (1993) Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci USA 90:8547-8551.
31. Sawa A and Snyder SH (2002) Schizophrenia: diverse approaches to a complex disease. Science 296:692-695. (Pubitemid 34441987)
32. Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, and Meltzer HY (2010) Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 332: 622-631.
33. Tsai G and Coyle JT (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165-179. (Pubitemid 34160524)
34. Wang X, Gu Z, Zhong P, Chen G, Feng J, and Yan Z (2006) Aberrant regulation of NMDA receptors by dopamine D4 signaling in rats after phencyclidine exposure. Mol Cell Neurosci 31:15-25. (Pubitemid 43049898)
35. Weinberger DR, Berman KF, and Zec RF (1986) Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 43:114-124. (Pubitemid 16163530)
36. Wenthold RJ, Prybylowski K, Standley S, Sans N, and Petralia RS (2003) Trafficking of NMDA receptors. Annu Rev Pharmacol Toxicol 43:335-358. (Pubitemid 37372645)
37. Xia YF, Kessler M, and Arai AC (2005) Positive alpha-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid (AMPA) receptor modulators have different impact on synaptic transmission in the thalamus and hippocampus. J Pharmacol Exp Ther 313:277-285. (Pubitemid 40411352)
38. 1A regulation of N-methyl-D-aspartate receptor channels in pyramidal neurons of prefrontal cortex. J Biol Chem 283:17194-17204.
39. 1Areceptors regulate NMDA receptor channels through a microtubule-dependent mechanism. J. Neurosci 25:5488-5501.
40. Yuen EY, Liu W, Karatsoreos IN, Feng J, McEwen BS, and Yan Z (2009) Acute stress enhances glutamatergic transmission in prefrontal cortex and facilitates working memory. Proc Natl Acad Sci USA 106:14075-14079.